Financial Performance - For the nine months ended September 30, 2020, the company reported a net loss of $57.2 million, with an accumulated deficit of approximately $741.3 million since inception in 2003[149]. - Net cash used in operating activities for the nine months ended September 30, 2020 was $40.0 million, compared to $29.2 million for the same period in 2019[183]. - The company anticipates that losses will continue for the foreseeable future, impacting cash requirements significantly[180]. - As of September 30, 2020, the accumulated deficit as of September 30, 2020 was approximately $741.3 million[186]. - Working capital as of September 30, 2020 was $135.8 million, an increase from $93.0 million as of December 31, 2019[186]. Research and Development - Research and development expenses for the three months ended September 30, 2020, increased by 62% to $13.968 million compared to $8.641 million in the same period of 2019[162]. - For the nine months ended September 30, 2020, research and development expenses rose by 38% to $38.725 million from $28.115 million in the prior year[163]. - The increase in research and development expenses for the three months ended September 30, 2020, was primarily due to $3.9 million in increased gene therapy manufacturing costs and $2.0 million related to increased headcount and facilities costs[162]. - The Controlled IL-12 platform is currently being evaluated in a Phase 1/2 clinical trial for the treatment of diffuse intrinsic pontine glioma (DIPG), with plans to dose up to 12 patients[147]. - The company is collaborating with the National Cancer Institute (NCI) on a Phase 2 clinical trial for autologous TCR-T therapies targeting neoantigens in solid tumors[155]. - Eden BioCell is preparing for a clinical trial of Sleeping Beauty-generated CD19-specific CAR+ T therapies in Taiwan, with preliminary observations supporting the benefit of the RPM technology[156]. - The company expects to initiate a clinical trial with MD Anderson for its Library TCR-T approach in mid-2021, targeting several cancer types[154]. Administrative Expenses - General and administrative expenses for the three months ended September 30, 2020 increased by 32% to $6.4 million compared to $4.8 million in the same period of 2019[172]. - General and administrative expenses for the nine months ended September 30, 2020 increased by 38% to $18.9 million compared to $13.7 million in the same period of 2019[173]. Financing Activities - The company completed a public offering of 29,110,111 shares at a price of $3.25, resulting in net proceeds of $88.7 million after expenses[178]. - Net cash provided by financing activities for the nine months ended September 30, 2020 was $101.7 million, compared to $56.1 million for the same period in 2019[185]. - The company continues to seek additional financial resources to fund product development, with potential delays in programs if sufficient capital is not obtained[152]. Operational Challenges - The company has implemented work-from-home policies due to the COVID-19 pandemic, which may negatively impact productivity and clinical program timelines[153]. - Management identified a material weakness in internal control over financial reporting as of September 30, 2020, affecting the accuracy of third-party clinical trial costs[203]. - The company has implemented measures to remediate the identified control deficiency, including training for accounting personnel[205]. Contractual Obligations - As of September 30, 2020, total contractual obligations amount to $9,743,000, with $4,062,000 due in less than one year[187]. - Operating leases total $3,157,000, with $1,128,000 due in less than one year[187]. - CRADA obligations total $3,125,000, with $2,500,000 due in less than one year[187]. - Royalty and license fees total $3,461,000, with $434,000 due in less than one year[187]. - The company is obligated to pay an annual licensing fee of $0.1 million under the License Agreement with PGEN[191]. - Minimum annual royalties of $0.3 million are required under the Patent License with the NCI, reducing to $0.1 million after cumulative payments of $1.5 million[192]. Currency and Risk Management - There were no off-balance sheet arrangements during the periods presented[194]. - The company has no clinical studies outside of the United States, minimizing currency exchange rate risk[197].

ZIOPHARM Oncology, Inc. (ZIOP) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Chris Taylor - VP, IR and Corporate Communications Laurence Cooper - CEO Sath Shukla - CFO Conference Call Participants Chris Howerton - Jeffries Thomas Flaten - Lake Street Capital Markets Yale Jen - Laidlaw & Company Operator Greetings, and welcome to the ZIOPHARM Oncology Second Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer ...

Second Quarter 2020 Financial Results and Update 06 August 2020 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's b ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of incorpor ...

ZIOPHARM Oncology, Inc. (ZIOP) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Laurence Cooper - Chief Executive Officer Satyavrat Shukla - Chief Financial Officer David Mauney - President Conference Call Participants Alethia Young - Cantor Fitzgerald David Novak - Raymond James Ramakanth Swayampakula - H.C. Wainwright & Co., LLC Thomas Flaten - Lake Street Capital Markets, LLC Yale Jen - Laidlaw & Co ...

First Quarter 2020 Financial Results and Update 07 May 2020 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's busin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of incorpo ...

Fourth Quarter and Full Year 2019 Results Call 02 March 2020 Forward Looking Statements This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," ...

ZIOPHARM Oncology, Inc. (ZIOP) Q4 2019 Results Conference Call March 2, 2020 4:30 PM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Laurence Cooper - Chief Executive Officer Sath Shukla - Executive Vice President, Chief Financial Officer David Mauney - President Conference Call Participants Yale Jen - Laidlaw & Company Thomas Flaten - Lake Street Capital Swayampakula Ramakanth - H.C. Wainwright Nick Abbott - Wells Fargo Operator Ladies and gentlemen, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Delaware 84-1475642 (State or Other Jurisdiction of Incorporation or Organization) One First Avenue, Parris Building 34, Navy Yard Plaza Boston, Massachusetts 02129 (Address of Principal Executive Offices) (Zip Code) FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...